BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for August:
FDA approval decision for Gilead Sciences' (GILD - Get Report) HIV drug Btripla. Aug. 20
FDA approval decision for Regeneron Pharmaceuticals (REGN) Eyelea for wet age-related macular degeneration.
FDA approval decision for Dendreon's (DNDN) Provenge manufacturing facility in Atlanta. Dendreon reports second-quarter results on Aug. 3.
FDA approval decision for Nupathe (PATH) migraine patch Zelrix. Aug. 30
FDA approval decision for Seattle Genetics' (SGEN - Get Report) lymphoma drug Adcetris. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.